
    
      PROTOCOL OUTLINE: The is a randomized, open label study. All patients receive a core regimen
      of clarithromycin and streptomycin. Patients are randomized into two treatment arms. Arm I
      patients receive rifampin and ethambutol. Arm II patients receive amithiozone.

      Patients are followed for one year to detect any relapse or other complications.

      Patients not eligible for this randomized study may be entered on a short open label study
      with amithiozone.

      Completion date provided represents the completion date of the grant per OOPD records
    
  